Congress looking for ‘simple solutions’ to Rx pricing quandary
Chad Landmon, Hatch-Waxman & Biologics Chair, discusses the recent bill passed by the U.S. Senate to limit biologic patent thickets and why he believes more drug price bills will be passed in the coming months.
